# US 2024/0197831 A1 · Combination therapy to treat erythropoietin-resistant anemia in chronic kidney disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197831 A1
- Document ID: US20240197831A1
- Status: Published application
- Kind: A1
- Application number: 18/538,174
- Filed: 2023-12-13
- Published: 2024-06-20
- Earliest claimed: 2022-12-16
- Assignees: The Chinese University of Hong Kong
- Applicants: The Chinese University of Hong Kong
- Inventors: Xiaoyu YAN; Raymond S.M WONG; Xiaoqing FAN; Huixi ZOU
- Web page: https://patentgrep.com/patent/US20240197831A1

## CPC

- A61K 38/196: {Thrombopoietin}
- A61K 38/1816: {Erythropoietin [EPO]}
- A61P 7/06: Antianaemics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The subject invention pertains to novel methods of treatment for subjects suffering from anemia, particularly as a result of erythropoiesis-stimulating agents (ESAs) resistant anemia. The methods comprise administering at least two compositions to a subject, in which the compositions can comprise a first composition comprising an ESA and a second composition comprising a thrombopoietin receptor agonist (TPO-RA). The combination of ESA with TPO-RA can stimulate the expansion of hematopoietic stem cells.

## Claims

### Claim 1

A method of treating erythropoiesis-stimulating agents resistant anemia in a subject comprising administering effective amounts of a first composition comprising an erythropoiesis-stimulating agent (ESA) and a second composition comprising a thrombopoietin receptor agonist (TPO-RA), wherein a dose of the ESA administered to the subject is about 0.01 mcg/kg to about 5 mcg/kg.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has chronic kidney disease.

### Claim 3 (depends on 1)

The method of claim 1, wherein the dose of the ESA administered to the subject is about 0.01 mcg/kg to about 2.50 mcg/kg.

### Claim 4 (depends on 3)

The method of claim 3, wherein the dose of the ESA administered to the subject is about 0.60 mcg/kg.

### Claim 5 (depends on 1)

The method of claim 1, wherein a dose of the TPO-RA administered to the subject is about 0.01 μg/kg to about 100 μg/kg.

### Claim 6 (depends on 5)

The method of claim 5, wherein the dose of the TPO-RA administered to the subject is about 1 μg/kg.

### Claim 7 (depends on 1)

The method of claim 1, wherein the first composition is administered thrice weekly.

### Claim 8 (depends on 1)

The method of claim 1, wherein the second composition is administered once every 4 weeks.

### Claim 9 (depends on 1)

The method of claim 1, wherein a first dose of the second composition is administered about two weeks after a first dose of the first composition.

### Claim 10 (depends on 1)

The method of claim 1, wherein the TPO-RA is romiplostim.

### Claim 11 (depends on 1)

The method of claim 1, wherein the ESA is a recombinant human erythropoietin (rHuEPO).

### Claim 12 (depends on 1)

The method according to claim 1, wherein the first composition and the second composition are administered by intravenous or subcutaneous administration.

### Claim 13 (depends on 1)

The method of claim 1, wherein the first composition and the second composition further comprise a pharmaceutically acceptable excipient and/or carrier.
